What's new

Orphan designation: human anti-promyostatin monoclonal antibody (apitegromab) Treatment of spinal muscular atrophy, 14/12/2018 Positive

Orphan designation: human anti-promyostatin monoclonal antibody (apitegromab) Treatment of spinal muscular atrophy, 14/12/2018 Positive

Feb 24, 2025 - 10:11
 0
Orphan designation: human anti-promyostatin monoclonal antibody (apitegromab) Treatment of spinal muscular atrophy, 14/12/2018 Positive
Orphan designation: human anti-promyostatin monoclonal antibody (apitegromab) Treatment of spinal muscular atrophy, 14/12/2018 Positive
Read More

Tags:

Previous Article

Maximise your retention and profits with EMaC

Next Article

Drones are the next chapter in US-India’s defense partnership

Related Posts

Veterinary medicines European public assessment report (EPAR): Icthiovac ERM, inactivated vaccine against yersiniosis , Status: Authorised

Veterinary medicines European public assessment report ...

Feb 24, 2025  0

Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 19, 2025  0

Clinical Trials Information System (CTIS) bitesize talk: Change of sponsor in CTIS, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 5 March 2025, 15:30 (CET) to 5 March 2025, 17:00 (CET)

Clinical Trials Information System (CTIS) bitesize talk...

Feb 9, 2025  0